JAMA

Charlie Health Now Serving Half of U.S. States with Expansion into Maryland and Wisconsin

Retrieved on: 
Thursday, August 3, 2023
American Medical Association, IOP, Entrepreneurship, JAMA, Research, Journal, Patient, Mental, Nursing

BOZEMAN, Mont., Aug. 3, 2023 /PRNewswire/ -- Charlie Health, the leading provider of virtual high-acuity mental healthcare for teens and young adults, today announced the expansion of its services into Maryland and Wisconsin.

Key Points: 
  • BOZEMAN, Mont., Aug. 3, 2023 /PRNewswire/ -- Charlie Health, the leading provider of virtual high-acuity mental healthcare for teens and young adults, today announced the expansion of its services into Maryland and Wisconsin.
  • With these new markets, Charlie Health has expanded its virtual intensive outpatient program (IOP) to reach half of the U.S. states, comprising a population of over 245 million.
  • "As the youth mental health crisis continues to unfold, we remain steadfast in our mission to connect teens and young adults nationwide to life-saving mental healthcare," says Carter Barnhart, Co-Founder and CEO of Charlie Health.
  • This escalating demand for mental health services has overwhelmed already-strained state resources in Maryland and Wisconsin, highlighting the urgent need for high-acuity interventions that are accessible and efficacious.

Evolent welcomes Toyin Ajayi to its Board of Directors

Retrieved on: 
Wednesday, July 26, 2023
JAMA, Medicaid, University, Stanford University, National Committee for Quality Assurance, The New England Journal of Medicine, University of Cambridge, EVH, American Medical Association, Medicare, National Committee, Journal, Patient, TEDMED, Quality assurance, Health, NYSE, Management, Nursing, Evol (Future album), City block

WASHINGTON, July 26, 2023 /PRNewswire/ -- Evolent Health Inc. (NYSE: EVH), a health care company that delivers proven value-based specialty care solutions to payers and providers, announced today that its Board of Directors has appointed Toyin Ajayi, M.D., as a new director, effective immediately. 

Key Points: 
  • WASHINGTON, July 26, 2023 /PRNewswire/ -- Evolent Health Inc. (NYSE: EVH), a health care company that delivers proven value-based specialty care solutions to payers and providers, announced today that its Board of Directors has appointed Toyin Ajayi, M.D., as a new director, effective immediately.
  • "We're delighted to welcome Toyin to the Evolent board," said Evolent Chair of the Board Cheryl Scott.
  • We are thrilled to welcome Toyin as a director " said Seth Blackley, co-founder and CEO of Evolent.
  • To learn more about the Evolent Board of Directors, visit https://www.evolenthealth.com/about-us/leadership-team .

Novel investigational postpartum depression pill showed rapid and significant improvement in depressive symptoms in Phase 3 clinical trial

Retrieved on: 
Wednesday, July 26, 2023
Mental Health, Research, Women, Clinical Trials, Health Insurance, Health, Consumer, Pharmaceutical, Science, GABA, PPD, Perseverance, JAMA, Depression, Diarrhea, NAS, Feinstein Institutes for Medical Research, Somnolence, COVID-19, Food and Drug Administration, Clinical trial, Urinary tract infection, Woman, DSM-IV codes, Multimedia, The American Journal of Psychiatry, Mother, American Medical Association, American Journal, Behavioural sciences, Dizziness, Journal, Patient, Zucker Hillside Hospital, Zuranolone, Grammatical mood, Nausea, Paper, FDA, Headache, Credit, Northwell Health, Safety, Medical research, Food, Female, Pharmaceutical industry, Birth control, MD, Psychiatry

Fourteen-day oral, at-home, treatment with zuranolone versus placebo resulted in statistically significant improvement in depressive symptoms, as measured by change from baseline in HAMD-17 total score.

Key Points: 
  • Fourteen-day oral, at-home, treatment with zuranolone versus placebo resulted in statistically significant improvement in depressive symptoms, as measured by change from baseline in HAMD-17 total score.
  • Results showed that 57 percent of the women taking zuranolone versus 38 percent of women taking placebo experienced a 50 percent or more improvement in their depressive symptoms at day 15.
  • The trial demonstrated the improvement in depressive symptoms with zuranolone at 30 mg versus placebo in patients with PPD and that zuranolone was generally well tolerated.
  • The SKYLARK and ROBIN clinical trials provide some of the most substantial results for improving depressive symptoms in women with PPD.

Sensible Care Answers the Call for Mental Health Care, Expands Teletherapy Services to Florida, North Carolina, and Nevada

Retrieved on: 
Wednesday, July 26, 2023
Army, TRICARE, Veteran, Patient, Mental, Health, PTSD, JAMA, Nursing

SANTA ANA, Calif., July 26, 2023  /PRNewswire-PRWeb/ -- Sensible Care, an end-to-end online behavioral health provider, today announced the expansion of its teletherapy services to residents of Florida, North Carolina, and Nevada. This significant expansion is part of Sensible Care's ongoing commitment to delivering high-quality teletherapy to individuals and communities in need, including active duty and retired service members and their families covered by TRICARE.

Key Points: 
  • Recent data reveals that a significant portion of TRICARE beneficiaries in both states face challenges in accessing adequate mental health care.
  • Nevada, with its unique demographics and growing population, is another area where Sensible Care is eager to extend its services.
  • Sensible Care significantly increases access to mental health care by delivering patient care via video and maximizing convenience with user-friendly online scheduling.
  • After grappling with PTSD and encountering challenges in accessing quality mental health care, Paul dedicated the next decade to studying the behavioral health industry before co-founding Sensible Care.

Sanguina Raises $2.8M in Series A Funding to Drive Innovation in Home-Based Testing and Wellness Management

Retrieved on: 
Tuesday, July 25, 2023
Health Technology, Technology, Apps, Applications, Other Consumer, General Health, Women, Medical Devices, Men, Artificial Intelligence, Baby, Maternity, Clinical Trials, Family, Biotechnology, Consumer, Health, Mobile, Wireless, Emory University, Dehydration, JAMA, Woman, Georgia Institute of Technology College of Design, Multimedia, Biomarker, Annals of Internal Medicine, Doctor of Philosophy, Aspirin, CDC, Child, American Medical Association, History of the Georgia Institute of Technology, Journal, MD, Anemia, Korea Disease Control and Prevention Agency, Internal medicine, Invention, Artificial intelligence, Conditional sentence, FDA, Nursing, Medical device

Sanguina, a leading biotech company focused on providing rapid home-based testing and management solutions, announced today the successful completion of its $2.8m Series A funding round.

Key Points: 
  • Sanguina, a leading biotech company focused on providing rapid home-based testing and management solutions, announced today the successful completion of its $2.8m Series A funding round.
  • The funding will be used to accelerate the development and expansion of Sanguina's innovative blood health management digital and at-home-based platforms.
  • With advancements in home testing and artificial intelligence, the management of anemia and other chronic conditions is moving towards preventive and personalized medicine.
  • With the successful launch of anemia management through the AnemoCheck app and point-of-care test, Sanguina has taken a major stride towards revolutionizing home-based testing and personalized disease management.

Northeast Delta HSA research published in JAMA Network Open

Retrieved on: 
Wednesday, July 19, 2023
JAMA Network Open, Overalls, COVID-19, Research, American Medical Association, Journal, Behavior, Patient, Health information management, JAMA, Medical device, Delta

MONROE, La., July 19, 2023 /PRNewswire-PRWeb/ -- The Journal of the American Medical Association's (JAMA) Network Open publishes Northeast Delta Human Services Authority's (NEDHSA) research entitled, "Association Between Telehealth and Missed Appointments Among Patients Experiencing Behavioral Health Challenges." NEDHSA's cohort study is a retrospective analysis of the electronic health records of patients with behavioral health conditions who scheduled appointments in outpatient clinics in rural Louisiana from May 1, 2022, to January 31, 2023. The study sample included 9,715 appointments (3,318 in-person and 6,397 telehealth). The no-show rate was 13 percent for in-person appointments and 17 percent for telehealth appointments.

Key Points: 
  • The Journal of the American Medical Association's (JAMA) Network Open publishes Northeast Delta Human Services Authority's (NEDHSA) research entitled, "Association Between Telehealth and Missed Appointments Among Patients Experiencing Behavioral Health Challenges."
  • MONROE, La., July 19, 2023 /PRNewswire-PRWeb/ -- The Journal of the American Medical Association's (JAMA) Network Open publishes Northeast Delta Human Services Authority's (NEDHSA) research entitled, "Association Between Telehealth and Missed Appointments Among Patients Experiencing Behavioral Health Challenges."
  • NEDHSA Executive Director Dr. Monteic A. Sizer said JAMA Network Open's publishing of the agency's research "validates our empirical focus and overall population health improvement desires in Louisiana's Delta.
  • To view the research in its entirety, please see the following link: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2807436

What Life-Threatening Condition Did Pope Francis, Brazil's President and Lisa Marie Presley All Share?

Retrieved on: 
Tuesday, July 18, 2023
Infection, Extrapyramidal system, Tubing (recreation), Pelvis, Stanford University, Woman, Infertility, Emergency department, Inflammation, Adhesion, Harvard University, Massage, Physical therapy, Bowel obstruction, World Journal of Gastroenterology, Female, JAMA, Birth control, Dentistry, U.S.A

GAINESVILLE, Fla., July 18, 2023 /PRNewswire/ -- Beloved singer and actress Lisa Marie Presley, Pope Francis and Brazil's ex-president Bolsonaro all faced life-threatening problems when scar tissue closed their intestines. Famous or not, nobody can live for long when their bowel is obstructed by scars called adhesions. While bowel repair is the 2nd most common Emergency Room surgery in the U.S.A. (JAMA Surgery), post-surgical scars are the primary cause of new obstructions. Thus, any treatment that can decrease adhesive obstructions without surgery has the potential to save lives for thousands of people.

Key Points: 
  • GAINESVILLE, Fla., July 18, 2023 /PRNewswire/ -- Beloved singer and actress Lisa Marie Presley, Pope Francis and Brazil's ex-president Bolsonaro all faced life-threatening problems when scar tissue closed their intestines.
  • Thus, any treatment that can decrease adhesive obstructions without surgery has the potential to save lives for thousands of people.
  • Recent studies on a new non-surgical bodywork developed to decrease adhesions is showing promising results for people with bowel obstructions.
  • "Adhesions can create glue-like internal bonds after surgery, injury, infection or inflammation," says physical therapist and study author Belinda Wurn.

Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

Retrieved on: 
Tuesday, July 18, 2023
APRE, Amgen, Euronext Amsterdam, SCIENCE, Howard Hughes, EGM, Massachusetts General Hospital, Research, Medical school, Onyx Pharmaceuticals, Doctor of Philosophy, Harvard Medical School, Rare, Editorial, Medical University of South Carolina, Internal medicine, Executive Committee, Faculty, PIC, S-1 Executive Committee, Hospital, Therapy, Merrimack Pharmaceuticals, JAMA, Management, Genzyme, Pharming, Sanofi, Pharmacology

Pharming nominates Dr. Peters for the appointment as Non-Executive Director for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM).

Key Points: 
  • Pharming nominates Dr. Peters for the appointment as Non-Executive Director for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM).
  • Until the appointment as Non-Executive Director by the EGM, Dr. Peters will join the Board of Directors as an Observer.
  • "After an extensive search, the Board is pleased to nominate Dr. Richard Peters as the new Chairman of the Board of Directors.
  • Dr. Richard Peters (60 years of age, Belgian national, US citizen) has over 30 years of experience in the healthcare industry and academia.

Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

Retrieved on: 
Tuesday, July 18, 2023
APRE, Amgen, Euronext Amsterdam, SCIENCE, Howard Hughes, EGM, Massachusetts General Hospital, Research, Medical school, Onyx Pharmaceuticals, Doctor of Philosophy, Harvard Medical School, Rare, Editorial, Medical University of South Carolina, Internal medicine, Executive Committee, Faculty, PIC, S-1 Executive Committee, Hospital, Therapy, Merrimack Pharmaceuticals, JAMA, Management, Genzyme, Pharming, Sanofi, Pharmacology

Pharming nominates Dr. Peters for the appointment as Non-Executive Director for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM).

Key Points: 
  • Pharming nominates Dr. Peters for the appointment as Non-Executive Director for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM).
  • Until the appointment as Non-Executive Director by the EGM, Dr. Peters will join the Board of Directors as an Observer.
  • "After an extensive search, the Board is pleased to nominate Dr. Richard Peters as the new Chairman of the Board of Directors.
  • Dr. Richard Peters (60 years of age, Belgian national, US citizen) has over 30 years of experience in the healthcare industry and academia.

ADDF Statement on New Results from Donanemab's TRAILBLAZER-ALZ 2 Trial

Retrieved on: 
Monday, July 17, 2023
Fillit, Optimism, JAMA, Alzheimer's Drug Discovery Foundation, Clinical trial, Ageing, Cancer, Research, Inflammation, Biomarker, Dementia, AAIC, Lilly, MD, Patient, Investment, Donanemab, Biology, Knowledge, Eli Lilly and Company, Entrepreneurship, FDA, III, Conference, Disease, Pharmaceutical industry, Medical imaging, Alzheimer's disease

NEW YORK, July 17, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported by Eli Lilly and Company today for its anti-amyloid drug, donanemab, which was unveiled at the Alzheimer's Association International Conference (AAIC) in Amsterdam and published in JAMA. The data serve as another proof point that anti-amyloid therapies are just the first class of disease modifying therapies, further validating the ADDF's cornerstone belief that Alzheimer's will need to be treated with combination therapy, like other complex diseases of aging.

Key Points: 
  • Like in cancer, the goal is to address the many underlying pathologies of the disease through a precision medicine approach."
  • "Advancements in clinical trial design have been a driving force behind the recent Alzheimer's breakthroughs, and there's still more progress to come," notes Dr. Fillit.
  • The results of the TRAILBLAZER-ALZ 2 trial accelerate recent momentum, bringing us one step closer to making Alzheimer's a treatable, and eventually, a preventable disease."
  • Lilly has submitted donanemab to the FDA for traditional approval and a decision is expected to be announced by the end of the year.